AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7608429
Drug: Aspirin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (200 mg/day)
Trial: 7608429
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus regular heparin (400 IU/kg body weight per day intravenously)
Trial: 7608429
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus low molecular weight heparin (214 UIC/kg anti‐Xa twice daily subcutaneously)
Trial: 23281243
Drug: Disease-modifying antirheumatic
RxNorm normalized name: ANTIRHEUMATICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying antirheumatic drugs (DMARDs)
Trial: 606780
Drug: Whole-virus vaccines
RxNorm normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virus vaccines (400 CCA units/0.5 ml or 200 CCA units/0.25 ml)
Trial: 606780
Drug: Ether-extracted, subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ether-extracted, subunit vaccines (with or without 1.5 mg of A1PO4/0.5 ml)
Trial: 606780
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of ether-extracted, subunit virus vaccine with Hsw1N1 antigen
Trial: 606780
Drug: Dosage regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage regimen of two doses administered at least four weeks apart
Trial: 30192341
Drug: Topical extra
RxNorm normalized name: GLYCERIN 13.226 g in 100 mL TOPICAL EXTRACT [WELLAGE 4D Gold Essence]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical extra virgin olive oil for massaging
Trial: 1696799
Drug: Piroxicam gel
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam gel
Trial: 30192341
Drug: Routine drugs
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drugs alone
Trial: 21395680
Drug: Tropisetron (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (5 mg/mL)
Trial: 17457134
Drug: Sodium parecoxib
RxNorm normalized name: parecoxib sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium parecoxib (1 mg/kg)
Trial: 15764246
Drug: 5'-DFUR administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'-DFUR administration
Trial: 7751425
Drug: IMDUR 60-mg
RxNorm normalized name: isosorbide mononitrate Extended Release Oral Tablet [Imdur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMDUR 60-mg tablets
Trial: 7751425
Drug: 5-ISMN 60-mg
RxNorm normalized name: ISMN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-ISMN 60-mg solution
Trial: 7751425
Drug: IMDUR 60-mg
RxNorm normalized name: isosorbide mononitrate Extended Release Oral Tablet [Imdur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMDUR 60-mg tablets with food
Trial: 7751425
Drug: IMDUR 60-mg
RxNorm normalized name: isosorbide mononitrate Extended Release Oral Tablet [Imdur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMDUR 60-mg tablets under fasted conditions
Trial: 31174889
Drug: ipafricept (IPA)
RxNorm normalized name: IPA
DrugBank: Ipafricept (DB15045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipafricept (IPA) in combination with carboplatin (C) and paclitaxel (P)
Trial: 22791118
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS), treated once daily for 4 weeks.
Trial: 22791118
Drug: Placebo, treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, treated once daily for 4 weeks.
Trial: 15361093
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection followed by graded pneumatic dilatation (PD) with 30 mm balloons
Trial: 7947417
Drug: Haloperidol treatment
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol treatment (on medication)
Trial: 7947417
Drug: Drug-free baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free baseline (off medication)
Trial: 2522902
Drug: Short-acting GnRH
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting GnRH agonist (100-500 micrograms daily)
Trial: 2976414
Drug: Long-acting GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting GnRH agonist (3.2 mg bolus)
Trial: 2976414
Drug: Combined GnRH-agonist/gonadotrophin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined GnRH-agonist/gonadotrophin stimulation
Trial: 27424879
Drug: Endodontic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endodontic therapy followed by extraction (Group B)
Trial: 22672237
Drug: 0.15 mol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mol L(‐1) HCl infusion
Trial: 18573823
Drug: Atorvastatin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin as add-on therapy to interferon-beta 1b
Trial: 16085593
Drug: mu-opioid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mu-opioid receptor binding in bulimic subjects
Trial: 8983446
Drug: Serum IL-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum IL-4 concentration (0.06 ng/ml)
Trial: 8983446
Drug: Serum GM-CSF
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum GM-CSF concentration (4.4 pg/ml)
Trial: 8195848
Drug: Brodimoprim (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodimoprim (single dose)
Trial: 8195848
Drug: Co-trimoxazole (trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (trimethoprim 160 mg + sulphamethoxazole 800 mg every 12 hours)
Trial: 8195848
Drug: Erythromycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (600 mg three times a day)
Trial: 3763654
Drug: 2% fusidic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% fusidic acid plus 0.1% betamethasone cream
Trial: 3763654
Drug: 0.1% gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% gentamicin plus 0.1% betamethasone cream
Trial: 25924781
Drug: CPAP (PEEP:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP (PEEP: 5 cm H2O, flow: 15 L/min, FiO2: 33 %) three times per week during hemodialysis sessions
Trial: 22177779
Drug: Selective endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective endoscopic treatment of non-refluxing contralateral ureters (NRCU) in patients deemed at high risk (H2 or H3)
Trial: 22177779
Drug: Observation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation of non-refluxing contralateral ureters (NRCU) without treatment
Trial: 21400196
Drug: 20,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20,000 IU vitamin D(3) weekly and 500 mg calcium daily for 96 weeks
Trial: 21400196
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and 500 mg calcium daily for 96 weeks
Trial: 16469753
Drug: CVD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD regimen (cisplatin 30 mg/m2 on days 1-3, vindesine 2.5 mg/m2 on day 1, dacarbazine 250 mg/m2 on days 1-3)
Trial: 7016150
Drug: Alprenolol (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprenolol (5-10 mg intravenously followed by 200 mg orally twice a day for one year)
Trial: 7016150
Drug: Placebo (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5-10 mg intravenously followed by placebo orally twice a day for one year)
Trial: 26605836
Drug: Aflibercept (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (2.0 mg)
Trial: 26048069
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) therapy with lidocaine and bupivacaine
Trial: 23835559
Drug: Modern knee
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern knee implant
Trial: 23835559
Drug: Traditional knee
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional knee implant
Trial: 19454394
Drug: Twice-daily insulin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily insulin lispro mix 75/25 plus metformin
Trial: 19454394
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times daily insulin lispro mix 50/50 plus metformin
Trial: 15531001
Drug: Rosuvastatin 10-40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10-40 mg
Trial: 15531001
Drug: Atorvastatin (milligram-equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (milligram-equivalent doses)
Trial: 15531001
Drug: Simvastatin (milligram-equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (milligram-equivalent or higher doses)
Trial: 15531001
Drug: Pravastatin (milligram-equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (milligram-equivalent or higher doses)
Trial: 3284726
Drug: Neostigmine, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine, 0.5 mg, administered intramuscularly every third hour on the third day after laparotomy, until passage of flatus or stools or a total of three injections
Trial: 31241854
Drug: Intradermal PRP
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal PRP alone
Trial: 31241854
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with subcision followed by PRP injection
Trial: 25497264
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment in diabetic patients
Trial: 25497264
Drug: Non-insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-insulin treatment in diabetic patients
Trial: 24432627
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate liquid (10 ml, bid) and vitamin E (100 mg, bid) for 3 months (Control)
Trial: 18156535
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg oral dexamethasone
Trial: 2931831
Drug: Baclofen (30-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (30-80 mg daily)
Trial: 27881108
Drug: Blended smoking
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended smoking cessation treatment (5 online sessions, 5 face-to-face sessions)
Trial: 27881108
Drug: Face-to-face smoking
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face smoking cessation treatment (10 face-to-face sessions)
Trial: 24549163
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of autologous bone marrow mononuclear cells (BMCs)
Trial: 20925951
Drug: Fractionated stereotactic
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated stereotactic radiotherapy (FSRT) with a total dose of 36 Gy in single doses of 2 Gy
Trial: 2710173
Drug: Calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium acetate (4.4 g, 25 mmol of calcium)
Trial: 30924600
Drug: Collagen matrix
RxNorm normalized name: Omeza Collagen Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen matrix implant (Ologen®; OLO)
Trial: 27889320
Drug: Two intraoperative,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two intraoperative, intravenous doses (IOIO)
Trial: 27889320
Drug: One preoperative
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One preoperative plus two intraoperative, intravenous doses (POIOIO)
Trial: 23025424
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of the dosing aid
Trial: 23025424
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of the dosing aid with the drop guider
Trial: 23025424
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of the dosing aid together with patient education
Trial: 23025424
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of the dosing aid and drop guider together with patient education
Trial: 21736730
Drug: Brief Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Intervention plus Cognitive Behavioral Treatment (CBT)
Trial: 21736730
Drug: Brief Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Intervention plus nutritional supplements of seal oil
Trial: 21736730
Drug: Brief Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Intervention plus nutritional supplements of soy oil
Trial: 16556690
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin (SC)
Trial: 17294445
Drug: LHT+IT-DC (intratumoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHT+IT-DC (intratumoral injection of autologous immature dendritic cells after local hyperthermia)
Trial: 17294445
Drug: IT-DC (intratumoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT-DC (intratumoral injection of autologous immature dendritic cells without local hyperthermia)
Trial: 15266633
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with 860 nm gallium/aluminum/arsenide laser at a dosage of 6 J/cm2, treated three times per week for 5 weeks.
Trial: 15266633
Drug: Sham laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham laser treatment, treated three times per week for 5 weeks.
Trial: 29661497
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy with irinotecan (CPT‐11; 60 mg/m2 intravenously on days 1 and 8) and nedaplatin (NDP; 80 mg/m2 intravenously on day 1), administered within 6 weeks after surgery and repeated every 28 days for up to 5 cycles.
Trial: 24846652
Drug: AMG 157
RxNorm normalized name: AMG 157
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMG 157 (700 mg)
Trial: 20183666
Drug: Treatment-related costs
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related costs
Trial: 15662232
Drug: Grape-seed polyphenols
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape-seed polyphenols (1000 mg/day)
Trial: 15662232
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamin C and grape-seed polyphenols
Trial: 16189176
Drug: GH administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH administration alone
Trial: 31263727
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic Acid (HA) injection
Trial: 10549114
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic Acid (HA) therapy
Trial: 7723158
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (maintaining hemoglobin values between 100 and 120 g/L)
Trial: 7723158
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (maintaining hemoglobin values between 70 and 90 g/L)
Trial: 6119940
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg of diazepam
Trial: 6119940
Drug: 3 X
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 10(‐1) mg/kg of fentanyl
Trial: 26802643
Drug: SQ grass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ grass sublingual immunotherapy (SLIT) tablet
Trial: 21652583
Drug: High-dose (HD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (HD) chemotherapy with PBSCs
Trial: 21652583
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (SD) chemotherapy
Trial: 18971768
Drug: Hypnotic induction
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic induction with analgesic suggestion
Trial: 18971768
Drug: Hypnotic induction
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic induction without analgesic suggestion
Trial: 18971768
Drug: Merged hypnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merged hypnosis groups (hypnotic induction with and without analgesic suggestion)
Trial: 14641849
Drug: Intradomestic residual
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradomestic residual spraying of lambda‐cyhalothrin, E.C., 25 mg/m2
Trial: 14641849
Drug: Spatial fogging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spatial fogging of fenitrothion around the houses at 30 g/ha
Trial: 14641849
Drug: Intradomestic residual
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradomestic residual spraying of lambda‐cyhalothrin three times a year, at a dose slightly greater than 25 mg/m2
Trial: 11200148
Drug: Oral fluoropyrimidines
RxNorm normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral fluoropyrimidines (UFT plus leucovorin, capecitabine, eniluracil plus oral 5‐FU)
Trial: 8975963
Drug: Erythromycin lactobionate
RxNorm normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin lactobionate 7 mg per kg
Trial: 1736348
Drug: Budesonide enema
RxNorm normalized name: budesonide Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide enema (2 mg/100 ml)
Trial: 6342163
Drug: Gentamicin-containing steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin-containing steroid ointment
Trial: 29679749
Drug: SC peginterferon
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC peginterferon beta-1a 125 mcg every two weeks
Trial: 29679749
Drug: SC interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC interferon beta-1a 44 mcg three times per week
Trial: 26937774
Drug: Energy drink
RxNorm normalized name: Boost Energy Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy drink (Red Bull, 500 ml)
Trial: 22993936
Drug: Cycloferon in
RxNorm normalized name: Cicloferon
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycloferon in the complex treatment
Trial: 17765564
Drug: Diluted Sanofi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted Sanofi Pasteur smallpox vaccine
Trial: 16324343
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg every night (Group B)
Trial: 16324343
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg every night (Group C)
Trial: 16324343
Drug: Basal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal treatment (Group A)
Trial: 10197569
Drug: Solid foods
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid foods (SF) twice daily from 4 to 6 months
Trial: 90217
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg twice a day
Trial: 25808169
Drug: D-cycloserine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (50 mg) and Placebo (PBO)
Trial: 22404704
Drug: Quetiapine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (300 or 600 mg/day)
Trial: 22820896
Drug: Orlistat 60
RxNorm normalized name: orlistat 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 60 mg
Trial: 9498448
Drug: Finlay Institute
RxNorm normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finlay Institute (Havana) vaccine